We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
ADLM 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bangs Laboratories Introduces UltraMod Microsphere Technology

By LabMedica International staff writers
Posted on 28 Jul 2026

Bangs Laboratories (Fishers, IN, USA) is introducing UltraMod, its next-generation microsphere platform for bead-based diagnostic assays, at ADLM 2026. The company is presenting the technology during the ADLM Lecture Series on July 28 at 12:30 p.m. in Exhibit Hall Theater 2.

The session, titled “Engineering a Better Bead: Introducing UltraMod Technology for Accelerated Development, Scaling, and Validation of Fit-for-Purpose Microspheres,” focuses on improving the development of microsphere reagents for clinical and laboratory applications. UltraMod is designed to address the time and variability associated with optimizing bead-based reagents for individual diagnostic assays.


Image: The UltraMod platform uses a modular development workflow that allows assay developers to systematically adjust microsphere characteristics (Photo courtesy of Bangs Laboratories)
Image: The UltraMod platform uses a modular development workflow that allows assay developers to systematically adjust microsphere characteristics (Photo courtesy of Bangs Laboratories)

The platform uses a modular development workflow that allows assay developers to systematically adjust microsphere characteristics, including magnetic separation speed, surface properties, and particle size. These attributes can be tailored to specific assay requirements while maintaining consistency between manufacturing lots.

During the presentation, Bangs Laboratories is sharing case studies showing how UltraMod’s modular design principles can be applied to ongoing reagent development programs. Attendees are also learning how the platform’s scaling strategies can be incorporated into existing workflows to reduce optimization cycles and shorten assay validation timelines.

The session additionally examines a validation framework aligned with regulatory expectations to help developers evaluate and select bead-based reagent platforms. The approach is intended to provide a more predictable path from early-stage microsphere optimization through manufacturing scale-up and validation.

Designed for assay developers, laboratory scientists, and diagnostics research and development professionals, the presentation highlights practical strategies for reducing reagent variability and supporting robust assay performance across research and clinical diagnostic settings. Bangs Laboratories provides custom particle engineering, reagent development, and microsphere and nanosphere products for diagnostic, biotechnology, and research applications.


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Steam Sterilizer
Hi Vac II Line
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control

Latest ADLM 2026 News

Werfen Displays Complete Solutions for Hemostasis, Acute Care, Transfusion, and Transplant Solutions
28 Jul 2026  |   ADLM 2026

OnsiteGene Unveils Handheld 10-Minute Real-Time PCR System
28 Jul 2026  |   ADLM 2026

Tactus AI Unveils Humanoid Assistant for Clinical Laboratory Bench Work
28 Jul 2026  |   ADLM 2026



PURITAN MEDICAL